UBS Initiates Coverage On Exelixis with Neutral Rating, Announces Price Target of $30
Portfolio Pulse from Benzinga Newsdesk
UBS has initiated coverage on Exelixis with a Neutral rating and set a price target of $30.
September 19, 2024 | 6:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS has initiated coverage on Exelixis with a Neutral rating and a price target of $30, indicating a balanced view on the stock's potential.
The Neutral rating suggests that UBS does not expect significant short-term movement in Exelixis's stock price. The price target of $30 provides a benchmark for investors, but the neutral stance indicates a balanced view on the stock's potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100